title: Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
abstract: OBJECTIVES. To study the efficacy and associated serum prolactin levels of ziprasidone and olanzapine treatment in drug-naïve schizophrenia patients. METHODS. All 78 inpatients with drug-naïve schizophrenia were recruited from the Department of Psychology, The Third Affiliated Hospital of Sun Yat-sen University. They were divided into either olanzapine group (n = 49 [24 men, 25 women]; mean [standard deviation] age, 24 [6] years) or ziprasidone group (n = 29 [14 men, 15 women]; mean [standard deviation] age, 23 [7] years), all of whom were treated for 4 weeks. The serum prolactin level, the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), and Clinical Global Impression-Improvement scores were measured before and at the end of treatment. RESULTS. In the olanzapine group, the respective mean (standard deviation) PANSS and CGI-S scores after the treatment (62 ± 15 and 3 ± 1) were significantly lower than those before the treatment (104 ± 14 and 6 ± 1) [p < 0.01]. In the ziprasidone group, the corresponding scores after the treatment (75 ± 20 and 4 ± 1) were also significantly lower than those before the treatment (104 ± 17 and 6 ± 1) [p < 0.01]. The decreases in mean (standard deviation) PANSS total (42 ± 17) and PANSS positive scores (12 ± 6) in the olanzapine group were significantly higher than those in the ziprasidone group (29 ± 12 and 6 ± 4, respectively) [p < 0.01]. The increase of serum prolactin in the ziprasidone female group (47 ± 51 µg/L) was significantly higher than that in the ziprasidone male group (17 ± 11 µg/L), the olanzapine male group (5 ± 16 µg/L), and the olanzapine female group (21 ± 34 µg/L) [p < 0.05]. CONCLUSIONS. Both ziprasidone and olanzapine are effective for treating drug-naïve acute schizophrenia, but olanzapine was superior to ziprasidone in terms of positive and general psychopathological symptoms. In women, ziprasidone was associated with greater changes in prolactin level than olanzapine.
authors.affiliation: Department of Psychology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
authors.forename: X L
authors.initials: XL
authors.lastname: Wu
authors.forename: J H
authors.initials: JH
authors.lastname: Wang
authors.forename: S H
authors.initials: SH
authors.lastname: Hu
authors.forename: J
authors.initials: J
authors.lastname: Tao
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D007406:Interview, Psychological; D008297:Male; D000077152:Olanzapine; D060735:Pharmacovigilance; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D011388:Prolactin / Q000097:blood*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D011388:Prolactin; D000077152:Olanzapine